Fish & Richardson P.C
P. Louis Myers, Ph.D, J.D.

Fish & Richardson is a national law firm with 300 lawyers in eight offices: Boston, Dallas, Delaware, New York, San Diego, Silicon Valley, Twin Cities, and Washington, DC. It is one of the largest firms practicing intellectual property, litigation, and corporate law. Founded in 1878, Fish & Richardson represented Thomas Edison, Alexander Graham Bell, and the Wright Brothers.

Fish & Richardson has one of the largest biotechnology practices in the country. The breadth of our technical expertise is unmatched, covering virtually all biotechnology-related areas. Most of the experts in the group hold Ph.D.'s in disciplines such as molecular biology, biochemistry, organic chemistry, immunology, and botany. The firm's biotechnology clients include corporations, small companies, universities, hospitals, individuals, and investment firms.

Intellectual property: Our broad-based intellectual property services for biotechnology companies include patent portfolio planning and analysis, opinions—including freedom to use, infringement and validity, and patentability opinions—patent-related analysis of competitive and other third-party positions, and patent portfolio analysis in connection with financing, evaluation, and acquisition of technology. Fish & Richardson attorneys created and regularly teach a course on "Biotechnology: Patents, Licensing & FDA Practice," part of Professor Irving Kayton's Patent Resources Group advanced curriculum.

Corporate: We provide biotechnology clients with legal advice for business strategy and structuring, drafting and negotiation of licensing agreements, and financing transactions. We are also experienced in mergers & acquisitions; because our corporate and securities lawyers work closely with our intellectual property lawyers, we have particular expertise in intellectual property “due diligence” in connection with mergers and acquisitions. We have handled a wide variety of securities offerings and can assist with virtually any type of business or employment agreement.

Litigation: We have extensive experience litigating disputes involving all types of intellectual property rights, including biotechnology, pharmaceutical, and chemical patent infringement cases.

www.fr.com

back to top

Invest Australia

Invest Australia, the Australian Government’s investment promotion agency, was established in 1997 and has helped a wide range of companies invest an estimated A$13 billion. We are currently working with companies on projects with potential investment in Australia of more than A$50 billion.

With investment specialists in 14 locations world-wide, our people understand the unique needs of each market and each industry sector, and have the business experience and industry knowledge you need to make the right decisions.

We offer specialist advice on Australia’s industry capabilities and strengths, arrange site visits and assist you to find the right joint venture partner in Australia. Invest Australia can also help cut through red tape and streamline project approval processes.
Invest Australia can provide important information about setting up a business including details on investment regulations, business costs, skills availability and taxation. We can also identify any relevant government industry assistance schemes and possible incentives.

Please visit us at www.investaustralia.gov.au for a detailed explanation of what we have to offer, or contact one of our offices in the USA:
San Francisco: +1 415 243 2071 (sanfrancisco@investaustralia.gov.au)
New York: +1 212 351 6570
(newyork@investaustralia.gov.au)

back to top

Katan Associates
Stan Yakatan, Chairman

Katan is a globally based advisory services organization that provides a variety of integrated and interdisciplinary business and financial services to developing, knowledge-based growth and biotechnology companies. Our clients will share in the diversified operational, financial and strategic experiences that Katan’s senior management has gained in their various roles with numerous companies. We have a proven track record of adding significant value to formative-stage companies, providing management, financial, business development and strategic basis for a company’s growth and success.

Katan assists in any of the following areas:

• Strategic decision making, formulation and development
• Business Plan development
• Capital formation strategies including merger, IPO, private placement and
• Corporate partnering
• Corporate structuring and interim management
• Market/Competition – evaluation, positioning
• Mergers and acquisitions from a buy or sell side perspective
• Technology and product portfolio assessment and protection
• Establishment of US partners for international companies
• Establishment of key contacts in business development areas
• Clinical and regulatory strategies for biopharmaceutical companies
• Establishment of US operations for foreign-based companies

www.katanassociates.com

back to top

Kirkpatrick & Lockhart LLP
Eileen Smith Ewing, Esq, Partner and Chair of the Life Sciences Practice Group.

Kirkpatrick & Lockhart LLP (“K&L”) comprises approximately 700 lawyers, including 251 partners, practicing in offices located in Boston, Dallas, Harrisburg, Los Angeles, Miami, Newark, New York, Pittsburgh, San Francisco and Washington.

K&L’s interdisciplinary Life Sciences Practice Group is a nationwide network of lawyers experienced in solving the complex legal and regulatory issues facing our pharmaceutical, biotechnology, health care, and medical device clients. We practice in areas as diverse as corporate and securities, intellectual property, regulatory compliance, litigation, environmental, real estate, and tax law, and apply cutting-edge technological and business savvy to the rapidly evolving life sciences industry.

Our Clients. We represent a wide variety of clients, including biotechnology start-ups, middle-market medical device companies, multi-national pharmaceutical companies academic and research institutions venture capital funds and angel investors. Our clients’ products and services span the fields of proteomics, genomics, bioinformatics, gene therapy, nanotechnology, diagnostics, recombinant vaccine development, pharmaceutical, drug delivery, and medical device development, nutraceuticals and food additives, and agricultural biotechnology.

Our Philosophy. We cannot serve our clients without understanding the complex domestic and foreign regulations, volatile capital and commercial market trends, and paradigm-shattering scientific advances which shape this industry. The breadth of our group - across legal practice areas, geographical regions, and life science industry sectors - continually exposes us to new information, while our shared commitment enables its rapid dissemination.

back to top